Translocation renal cell carcinoma: Lack of negative impact due to lymph node spread

Cancer

Volumn 112, Issue 7, 2008, Pages 1607-1616

  Geller, James I ^a,c   Argani, Pedram ^b   Adeniran, Adebowale ^a   Hampton, Edith ^a   De Marzo, Angelo ^b   Hicks, Jessica ^b   Collins, Margaret H ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Adjuvant therapy; Lymph node; Pediatric; Renal cell carcinoma; Translocation morphology

Indexed keywords

GENE PRODUCT; PROTEIN TFE; UNCLASSIFIED DRUG;

ADOLESCENT; ANASTOMOSIS; ARTICLE; CANCER STAGING; CHILD; CHILDHOOD CANCER; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CYTOGENETICS; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GENE TRANSLOCATION; GENETIC SCREENING; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; KIDNEY CARCINOMA; LYMPH NODE METASTASIS; MALE; MEDICAL LITERATURE; PAPILLARY CARCINOMA; PEDIATRIC HOSPITAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; WORLD HEALTH ORGANIZATION;

ADENOCARCINOMA, CLEAR CELL; ADOLESCENT; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; CARCINOMA, PAPILLARY; CARCINOMA, RENAL CELL; CHILD; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; KIDNEY NEOPLASMS; LEUCINE ZIPPERS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR; NEOPLASM PROTEINS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSLOCATION, GENETIC;

EID: 41149136775     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23331     Document Type: Article

References (46)

1. Geller JI, Dome JS. Local lymph node involvement does not predict poor outcome in pediatric renal cell carcinoma. Cancer. 2004;101:1575-1583.
2. Selle B, Furtwangler R, Graf N, Kaatsch P, Bruder E, Leuschner I. Population-based study of renal cell carcinoma in children in Germany, 1980-2005: more frequently localized tumors and underlying disorders compared with adult counterparts. Cancer. 2006;107:2906-2914.
3. Ries LAG, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review, 1975-2000. Available at: http://seer.cancer.gov/csr/1975_2000/sections.html [accessed April 13, 2004].
4. Carcao MD, Taylor GP, Greenberg ML, et al. Renal-cell carcinoma in children: a different disorder from its adult counterpart? Med Pediatr Oncol. 1998;31:153-158.
5. Indolfi P, Terenziani M, Casale F, et al. Renal cell carcinoma in children: a clinicopathologic study. J Clin Oncol. 2003;21:530-535.
6. Ramphal R, Pappo A, Zielenska M, Grant R, Ngan BY. Pediatric renal cell carcinoma: clinical, pathologic, and molecular abnormalities associated with the members of the Mit transcription factor family. Am J Clin Pathol. 2006;126:349-364.
7. Castellanos RD, Aron BS, Evans AT. Renal adenocarcinoma in children: incidence, therapy and prognosis. J Urol. 1974;111:534-537.
8. Goto S, Ikeda K, Nakagawara A, Daimaru Y, Tsuneyoshi M, Enjoji M. Renal cell carcinoma in Japanese children. J Urol. 1986;136:1261-1263.
9. Booth CM. Renal parenchymal carcinoma in children. Br J Surg. 1986;73:313-317.
10. Senga Y, Taguchi H, Asao T, Misugi K. Undifferentiated renal cell carcinoma in infancy: report of a case and review of literature. Pediatr Pathol. 1986;5:157-165.
11. Dehner LP, Leestma JE, Price EB Jr. Renal cell carcinoma in children: a clinicopathologic study of 15 cases and review of the literature. J Pediatr. 1970;76:358-368.
12. Ficarra V, Righetti R, Pilloni S, et al. Prognostic factors in patients with renal cell carcinoma: retrospective analysis of 675 cases. Eur Urol. 2002;41:190-198.
13. Zisman A, Pantuck AJ, Chao DH, et al. Renal cell carcinoma with tumor thrombus: is cytoreductive nephrectomy for advanced disease associated with an increased complication rate? J Urol. 2002;168:962-967.
14. Altinok G, Kattar MM, Mohamed A, Poulik J, Grignon D, Rabah R. Pediatric renal carcinoma associated with Xp11.2 translocation/TFE3 gene fusions and clinicopathologic associations. Pediatr Dev Pathol. 2005;8:168-180.
15. Bruder E, Passera O, Harms D, et al. Morphologic and molecular characterization of renal cell carcinoma in children and young adults. Am J Surg Pathol. 2004;28:1117-1132.
16. Renshaw AA, Granter SR, Fletcher JA, Kozakewich HP, Corless CL, Perez-Atayde AR. Renal cell carcinomas in children and young adults: increased incidence of papillary architecture and unique subtypes. Am J Surg Pathol. 1999;23:795-802.
17. Argani P, Ladanyi M. Translocation carcinomas of the kidney. Clin Lab Med. 2005;25:363-378.
18. Argani P. The evolving story of renal translocation carcinoma. Am J Clin Pathol. 2006;126:332-334. Comment on: Am J Clin Pathol. 2006;26:349-364.
19. Geller JI, Khoury JD, Dome JS. Local lymph node involvement does not predict poor outcome in pediatric renal cell carcinoma. Author's reply [letter]. Cancer. 2005;103:1318.
20. Argani P, Lal P, Hutchinson B, Lui MY, Reuter VE, Ladanyi M. Aberrant nuclear immunoreactivity for TFE3 and neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay. Am J Surg Pathol. 2003;27:750-761.
21. Argani P, Lae M, Hutchinson B, et al. Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR. Am J Surg Pathol. 2005;29:230-240.
22. Guinan P, Sobin LH, Algaba F, et al. TNM staging of renal cell carcinoma: Workgroup No. 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997;80:992-993.
23. Huang FS, Zwerdling T, Stern LE, Ballard ET, Warner BW. Renal cell carcinoma as a secondary malignancy after treatment of acute promyelocytic leukemia. J Pediatr Hematol Oncol. 2001;23:609-611.
24. Argani P, Lae M, Ballard ET, et al. Translocation carcinomas of the kidney after chemotherapy in childhood. J Clin Oncol. 2006;24:1529-1534.
25. Chian-Garcia CA, Torres-Cabala CA, Eyler R, et al. Renal cell carcinoma in children and young adults: a clinicopathologic and immunohistochemical study of 14 cases [abstract]. Mod Pathol. 2003;16:145A.
26. Argani P, Antonescu CR, Illei PB, et al. Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. Am J Pathol. 2001;159:179-192.
27. Meloni AM, Dobbs RM, Pontes JE, Sandberg AA. Translocation (X;1) in papillary renal cell carcinoma. A new cytogenetic subtype. Cancer Genet Cytogenet. 1993;65:1-6.
28. Tomlinson GE, Niesen PD, Timmons CF, Schneider NR. Cytogenetics of a renal cell carcinoma in a 17-month-old child. Evidence for Xp11.2 as a recurring breakpoint. Cancer Genet Cytogenet. 1991;57:11-17.
29. Sidhar SK, Clark J, Gill S, et al. The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene. Hum Mol Genet. 1996;5:1333-1338.
30. Weterman MA, Wilbrink M, Geurts van Kessel A. Fusion of the transcription factor TFE3 gene to a novel gene, PRCC, in t(X;1)(p11;q21)-positive papillary renal cell carcinomas. Proc Natl Acad Sci U S A. 1996;93:15294-15298.
31. Perot C, Boccon-Gibod L, Bouvier R, et al. Five new cases of juvenile renal cell carcinoma with translocations involving Xp11.2: a cytogenetic and morphologic study. Cancer Genet Cytogenet. 2003;143:93-99.
32. Kuiper RP, Schepens M, Thijssen J, et al. Upregulation of the transcription factor TFEB in t(6;11)(p21;q13)-positive renal cell carcinomas due to promoter substitution. Hum Mol Genet. 2003;12:1661-1669.
33. Argani P, Hawkins A, Griffin CA, et al. A distinctive pediatric renal neoplasm characterized by epithelioid morphology, basement membrane production, focal HMB45 immunoreactivity, and t(6;11)(p21.1;q12) chromosome translocation. Am J Pathol. 2001;158:2089-2096.
34. Dal Cin P, Stas M, Sciot R, De Wever I, Van Damme B, Van den Berghe H. Translocation (X;1) reveals metastasis 31 years after renal cell carcinoma. Cancer Genet Cytogenet. 1998;101:58-61.
35. Perot C, Bougaran J, Boccon-Gibod L, et al. Two new cases of papillary renal cell carcinoma with t(X;1)(p11;q21) in females. Cancer Genet Cytogenet. 1999;110:54-56.
36. Garcia JA, Rini BI. Recent progress in the management of advanced renal cell carcinoma. CA Cancer J Clin. 2007;57:112-125.
37. Johnsen JA, Hellsten S. Lymphatogenous spread of renal cell carcinoma: an autopsy study. J Urol. 1997;157:450-453.
38. Schafhauser W, Ebert A, Brod J, Petsch S, Schrott KM. Lymph node involvement in renal cell carcinoma and survival chance by systematic lymphadenectomy. Anticancer Res. 1999;19:1573-1578.
39. Blom JH, van Poppel H, Marechal JM, et al. Radical nephrectomy with and without lymph node dissection: preliminary results of the EORTC randomized phase III protocol 30881. EORTC Genitourinary Group. Eur Urol. 1999;36:570-575.
40. Terrone C, Guercio S, De Luca S, et al. The number of lymph nodes examined and staging accuracy in renal cell carcinoma. BJU Int. 2003;91:37-40.
41. Ebert A, Gravou C, Stumpfl M, Rosch WH. Renal cell carcinoma in childhood. Case report and review [in German]. Urologe A. 2003;42:263-268.
42. Bauer M, Reaman GH, Hank JA, et al. A phase II trial of human recombinant interleukin-2 administered as a 4-day continuous infusion for children with refractory neuroblastoma, non-Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A Childrens Cancer Group study. Cancer. 1995;75:2959-2965.
43. MacArthur CA, Isaacs H Jr, Miller JH, Ozkaynak F. Pediatric renal cell carcinoma: a complete response to recombinant interleukin-2 in a child with metastatic disease at diagnosis. Med Pediatr Oncol. 1994;23:365-371.
44. Lae M, Argani P, Olshen AB, et al. Global gene expression profiles of renal carcinomas with Xp11 translocations (TFE3 gene fusions) suggest a closer relationship to alveolar soft part sarcomas than adult type renal cell carcinomas [abstract]. Mod Pathol. 2004;17(Suppl 1):163A.
45. Tsuda M, Davis IJ, Argani P, et al. TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition Cancer Res. 2007;67:919-929.
46. Weterman MA, van Groningen JJ, Tertoolen L, van Kessel AG. Impairment of MAD2B-PRCC interaction in mitotic checkpoint defective t(X;1)-positive renal cell carcinomas. Proc Natl Acad Sci U S A. 2001;98:13808-13813.